3 days ago · MB-105 is March Biosciences’ first-in-class CD5-targeted chimeric antigen receptor(CAR) T-cell therapy. Phase 2 development of MB-105 is planned to advance in a clinical trial in early 2025. The FDA has granted orphan drug designation to MB-105, a first-in-class CD5-targeted CAR T-cell therapy, for the treatment of patients with relapsed ...

MB-105 is March Bio's lead program, launched from the Center for Cell and Gene Therapy (Baylor College of Medicine, Houston Methodist Hospital, Texas Children's Hospital). The company recently closed a $28.4 million Series A financing to advance Phase 2 development of MB-105 and strengthen its manufacturing capabilities to support future ...

4 days ago · MB-105 is a first-in-class autologous CD5-targeted CAR-T cell therapy in development for CD5-positive hematologic malignancies, including T-cell lymphoma (TCL), T-cell acute lymphoblastic leukemia ...

3 days ago · MB-105 targets CD5, a widely expressed antigen in T-cell malignancies, offering potential therapeutic benefits for TCL, T-ALL, CLL, and MCL. The therapy's proprietary CAR design allows selective targeting of malignant cells, preserving some normal T-cell functions.

Oct 26, 2020 · The Phase 1 clinical trial of MB-105 will continue to enroll up to 33 patients. Its primary endpoints are to define safety and optimal dosing of PSCA CAR T cells in treating patients with PSCA-positive mCRPC.

MB-105 is a CD5 CAR T-cell technology invented at Baylor College of Medicine. It is in the clinic for the treatment of T-cell lymphoma (TCL) and T-cell acute lymphoblastic leukemia (T-ALL).

Nov 5, 2024 · The primary objectives are to confirm safety of the recommended dose of MB-105 in the safety run-in (using CTCAE V5 and ASTCT grading), then to evaluate efficacy in Simon stages 1 and 2 per independent central review, using Lugano 2014 and the global criteria (Cheson 2014, Olsen 2022).

Feb 15, 2022 · The Phase 1 clinical trial of MB-105 will continue to enroll up to 33 patients. Its primary endpoints are to define safety and optimal dosing of PSCA CAR T cells in treating patients with PSCA-positive mCRPC.

3 days ago · March Biosciences received FDA orphan drug designation for MB-105, its CD5-targeted CAR-T cell therapy for relapsed/refractory CD5-positive T-cell lymphoma. The company is preparing to advance MB-105 to a Phase 2 clinical trial in early 2025, following a recently closed Series A financing round of $28.4 million. This designation acknowledges the unmet need for new treatments

Sep 23, 2019 · The dosing of the first patients in this Phase 1 clinical trial evaluating MB-105 in PSCA-positive castration-resistant prostate cancer is a pivotal step toward better understanding its potential to help a wide range of patients with limited treatment options.”